The Israel Patent Office has granted the Company’s patent for its invention, titled “ Methods and Compositions for Oral Administrations of Exenatide.” (Oramed)
Diabetes News
Tag: GLP1
Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study
A short course of treatment with GLP-1 RA, besides weight loss, induces a redistribution of adipose tissue deposits, possibly contributing to a better cardiovascular risk profile in patients with type 2 diabetes mellitus (Acta Diabetologica)